Trial reportBMC gastroenterology2014
Determination of the discriminant score of intestinal microbiota as a biomarker of disease activity in patients with ulcerative colitis.
Trial report in BMC gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Inflammatory bowel diseases · 2021Pooled it
- Advances and optimization strategies in bacteriophage therapy for treating inflammatory bowel disease.Frontiers in immunology · 2024Review
- Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease.Intestinal research · 2024Review
- Bariatric Surgery and Inflammatory Bowel Disease: National Trends and Outcomes Associated with Procedural Sleeve Gastrectomy vs Historical Bariatric Surgery Among US Hospitalized Patients 2009-2020.Obesity surgery · 2023Article
- Functional Plasmon-Activated Water IncreasesInternational journal of molecular sciences · 2022Article
- Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease.Microorganisms · 2021Review
- Gut dysbiosis and clinical phases of pancolitis in patients with ulcerative colitis.MicrobiologyOpen · 2021Article
- Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease.Frontiers in nutrition · 2021Review
- The association among enterobacterial flora, dietary factors, and prognosis in patients with ulcerative colitis.Journal of clinical biochemistry and nutrition · 2020Article
- Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.World journal of gastroenterology · 2016Review
- Metabolic Interaction of Helicobacter pylori Infection and Gut Microbiota.Microorganisms · 2016Review
- Inter- and intra-individual variations in seasonal and daily stabilities of the human gut microbiota in Japanese.Archives of microbiology · 2015Article
- Human microbiome: From the bathroom to the bedside.World journal of gastrointestinal pathophysiology · 2015Review
- Nutritional Modulation of Gene Expression: Might This be of Benefit to Individuals with Crohn's Disease?Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, the gut microbiota has been found to provide an important link to the development of inflammatory bowel diseases (IBD) like ulcerative colitis (UC). Accordingly, inter-individual variation in the gut microbial community may be linked to inter-individual variation in the risk of IBD or other diseases. Further, the Terminal Restriction Fragment Length Polymorphism (T-RFLP) is a molecular biology technique for profiling bacterial species in faecal samples. This study was to evaluate a biomarker based on intestinal microbiota.
methodsThe study subjects were 69 patients with UC together with 80 relatives as controls. Twenty-three patients had active UC (group I) and 46 had quiescent UC (group II). The later included 17 patients with mild inflammation in the large intestine (group IIa), 29 without inflammation (group IIb). The patients' relatives were consanguineous (group III, n = 47), and non-consanguineous (group IV, n = 33). Faecal samples were obtained from all subjects for the investigation of intestinal microbiota by applying the T-RFLP method. The Discriminant analysis of operational-taxonomic-unit (OTU) on T-RFLP fingerprints was performed. The Canonical Discriminant Function Coefficient (Df) for each OTU was calculated. The individual OTUs were multiplied by the Df value, and the sum was termed the Discriminant Score (Ds).
resultsThe Ds decreased thus: group I > group IIa > group IIb > group III > group IV. Significant difference was calculated for group I vs group IV (P < 0.01), group I vs group IIb (P < 0.05), group I vs group III (P < 0.01), group IIa vs IV (P < 0.01), group IIb vs group IV (P < 0.01), group III vs group IV (P < 0.01), indicating a strong association between gut microbial species and the development of UC.
conclusionsIn this study, the Ds related to UC, or otherwise absence of UC in the five groups. Potentially, Ds may become a clinically relevant biomarker of disease activity in UC. To our knowledge, this is the first application of the Ds to the study of microbiota in UC patients, consanguineous and non-consanguineous relatives.
trial registrationClinical trial No: UMIN 000004123.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.